Last year, the Helsinki-based company began a Phase I study of lead compound CGTG-102, a GM-CSF-armed oncolytic adenovirus, in solid tumors

The Oslo, Norway-based company's next step will be to work closely with its partner Bayer to launch the product

Ablynx NV, of Ghent, Belgium, initiated preclinical development of next-generation anti-IgE Nanobody ALX-0962 in severe allergic asthma. ALX-0962 consists of a potent anti-IgE Nanobody with a dual mode of action – the ability to bind with high affinity to IgE while also displacing receptor-bound IgE – together with a serum albumin binding Nanobody for in vivo plasma half-life extension. BioAlliance Pharma SA, of Paris, reported the International Independent Board of Experts' data and safety

The Lyon, France-based company added a further €11 million, mostly through the conversion of bonds, providing sufficient funding to take the lead program Graspa through to approval in Europe and to start a U.S. Phase Ib trial of the product in the treatment of acute lymphoblastic leukemia (ALL

The Redwood City, Calif.-based company raised $65 million in a Series D financing in November to support the trial. (See BioWorld Today, Nov. 14, 2012.) The product is a combination of a long-acting muscarinic antagonist (LAMA), glycopyrrolate, and a long-acting beta-2 agonist (LABA), formoterol fumarate, a pair of medicines believed to have great potential for COPD in combination

The Lyon, France-based company added a further €11 million, mostly through the conversion of bonds, providing sufficient funding to take the lead program Graspa through to approval in Europe and to start a U.S. Phase Ib trial of the product in the treatment of acute lymphoblastic leukemia (ALL

MyeloXen is based on the company's ImuXen liposomal technology

The Carlsbad, Calif.-based company priced an underwritten public offering of 9 million shares of its common stock at $19 per share, seeking to raise $171 million from the offering, which is expected to close on or about May 14

The shares comprise just under 10 percent of the issued equity and bring the total number of shares in the Mechelen, Belgium-based company to 29.7 million

The spur for raising more money was the validation of Symphogen's antibody mixtures technology in a $632 million deal the Lyngby, Demark-based company inked with Merck KGaA in September 2012

GSK is a research partner of CluePoints Inc., a Cambridge, Mass.-based company Busye founded to develop an automated system for statistical monitoring of clinical trial data

Menarini CEO Andrew Slade noted that many in the audience would not be familiar with the Florence, Italy-based company, nor associate it with biologics

market, the Jerusalem-based company opted to go the new biologic route

Along the way, the Boulder, Colo.-based company attracted $60 million in private capital and is making steady progress in its goal to increase endogenous nitrous oxide (NO) by targeting GSNO, the major reservoir of NO in the body

The shares comprise just under 10 percent of the issued equity and bring the total number of shares in the Mechelen, Belgium-based company to 29.7 million

The spur for raising more money was the validation of Symphogen's antibody mixtures technology in a $632 million deal the Lyngby, Demark-based company inked with Merck KGaA in September 2012

The South San Francisco-based company said the CRL requested additional clinical data demonstrating both the ability of Probuphine to show opioid blockade of relevant doses of agonists and the effect of Probuphine at higher doses than studied to approximate blood plasma levels associated with daily 12 mg to 16 mg sublingual doses of buprenorphine

Menarini CEO Andrew Slade noted that many in the audience would not be familiar with the Florence, Italy-based company, nor associate it with biologics

for the Brisbane, Australia-based company's Diversity Scanning Array (DSA) and Versatile Assembly on Stable Templates (VAST) technologies in a deal worth up to $240 million in milestones, plus other payments